- Home
- SCLX vs SCOR Comparison
SCLX vs SCOR Comparison
Compare SCLX & SCOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- SCOR
- Stock Information
- Founded
- SCLX 2011
- SCOR 1999
- Country
- SCLX United States
- SCOR United States
- Employees
- SCLX N/A
- SCOR N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- SCOR Business Services
- Sector
- SCLX Health Care
- SCOR Consumer Discretionary
- Exchange
- SCLX Nasdaq
- SCOR Nasdaq
- Market Cap
- SCLX 35.7M
- SCOR 34.6M
- IPO Year
- SCLX N/A
- SCOR 2007
- Fundamental
- Price
- SCLX $26.28
- SCOR $6.80
- Analyst Decision
- SCLX Strong Buy
- SCOR
- Analyst Count
- SCLX 3
- SCOR 0
- Target Price
- SCLX $367.50
- SCOR N/A
- AVG Volume (30 Days)
- SCLX 230.4K
- SCOR 7.8K
- Earning Date
- SCLX 08-13-2025
- SCOR 11-11-2025
- Dividend Yield
- SCLX N/A
- SCOR N/A
- EPS Growth
- SCLX N/A
- SCOR N/A
- EPS
- SCLX N/A
- SCOR N/A
- Revenue
- SCLX $44,236,000.00
- SCOR $358,513,000.00
- Revenue This Year
- SCLX $89.26
- SCOR $3.45
- Revenue Next Year
- SCLX $203.95
- SCOR $2.59
- P/E Ratio
- SCLX N/A
- SCOR N/A
- Revenue Growth
- SCLX N/A
- SCOR N/A
- 52 Week Low
- SCLX $3.60
- SCOR $4.39
- 52 Week High
- SCLX $41.30
- SCOR $8.99
- Technical
- Relative Strength Index (RSI)
- SCLX 76.74
- SCOR 58.42
- Support Level
- SCLX $23.90
- SCOR $6.30
- Resistance Level
- SCLX $19.73
- SCOR $6.50
- Average True Range (ATR)
- SCLX 1.85
- SCOR 0.21
- MACD
- SCLX 0.50
- SCOR -0.04
- Stochastic Oscillator
- SCLX 91.79
- SCOR 79.71
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About SCOR comScore Inc.
comScore Inc is a United States-based information and analytics company that measures advertising, content, and the consumer audiences of each across media platforms. The platforms it measures include televisions, mobile devices, computers, tablets, CTV devices, and movie theaters. The company generates almost all its revenue from the United States, followed by Europe, Latin America, Canada, and other regions. It provides solutions for the automotive, digital media, financial services, pharmaceutical, retail, technology, travel, and other industries.